Evidence map›Paper›PMID 34978488›Full record

ArticleThe Journal of urology2022

Association between Treatment for Localized Prostate Cancer and Mental Health Outcomes.

Amy N Luckenbaugh, Christopher J D Wallis, Li-Ching Huang, Daniela Wittmann, Zachary Klaassen, Zighuo Zhao, Tatsuki Koyama, Aaron A Laviana, Ralph Conwill, Michael Goodman and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of urology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Amy N LuckenbaughDepartment of Urology, Vanderbilt University Medical Center, Nashville, Tennessee.ORCID 0000-0001-6598-9372
Christopher J D WallisDepartment of Urology, Vanderbilt University Medical Center, Nashville, Tennessee.
Li-Ching HuangDepartment of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee.
Daniela WittmannDepartment of Urology, University of Michigan Medical Center, Ann Arbor, Michigan.
Zachary KlaassenDivision of Urology, Medical College of Georgia at Augusta University, Augusta, Georgia.
Zighuo ZhaoDepartment of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee.
Tatsuki KoyamaDepartment of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee.
Aaron A LavianaDepartment of Surgery and Perioperative Care, Dell Medical School, Austin, Texas.
Ralph ConwillOffice of Patient and Community Education, Patient Advocacy Program, Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee.
Michael GoodmanDepartment of Epidemiology, Emory University Rollins School of Public Health, Atlanta, Georgia.
Ann S HamiltonDepartment of Preventive Medicine, Keck School of Medicine at the University of Southern California, Los Angeles, California.
Xiao-Cheng WuDepartment of Epidemiology, Louisiana State University Health Sciences Center New Orleans School of Public Health, New Orleans, Louisiana.
Lisa E PaddockDepartment of Epidemiology, Cancer Institute of New Jersey, Rutgers Health, New Brunswick, New Jersey.
Antoinette StroupDepartment of Epidemiology, Cancer Institute of New Jersey, Rutgers Health, New Brunswick, New Jersey.
Matthew R CooperbergDepartment of Urology, University of California, San Francisco, California.
Mia HashibeDepartment of Family and Preventative Medicine, University of Utah School of Medicine, Salt Lake City, Utah.
Brock B O'NeilDepartment of Urology, University of Utah Health, Salt Lake City, Utah.
Sherrie H KaplanDepartment of Medicine, University of California Irvine, Irvine, California.
Sheldon GreenfieldDepartment of Medicine, University of California Irvine, Irvine, California.
Karen E HoffmanDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
David F PensonDepartment of Urology, Vanderbilt University Medical Center, Nashville, Tennessee.
Daniel A BarocasDepartment of Urology, Vanderbilt University Medical Center, Nashville, Tennessee.

Funding

Comparative Effectiveness of Treatments for Localized Prostate CancerR01HS019356 · AHRQ · VANDERBILT UNIVERSITY · PI PENSON, DAVID F. · 2010 to 2010
$7.6M
Surgical Oncology Training GrantT32CA106183 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI James Richard Goldenring · 2004 to 2026
$6.0M
10-year Comparative Effectiveness and Harms of Treatments for Prostate CancerR01CA230352 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BAROCAS, DANIEL A · 2019 to 2023
$3.1M
Comparative Effectiveness of Modern Therapies for Localized Prostate CancerR01HS022640 · AHRQ · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PENSON, DAVID F. · 2013 to 2013
$1.8M
AHRQ HHS R01 HS019356AHRQ HHS R01 HS022640NCI NIH HHS R01 CA230352NCI NIH HHS T32 CA106183
6 · The paper itself

Abstract

purposeWe aimed to compare patient-reported mental health outcomes for men undergoing treatment for localized prostate cancer longitudinally over 5 years. MATERIALS AND

methodsWe conducted a prospective population-based analysis using the Comparative Effectiveness Analysis of Surgery and Radiation (CEASAR) study. Patient-reported depressive symptoms (Centers for Epidemiologic Studies Depression [CES-D]) and domains of the Medical Outcomes Study 36-item Short Form survey evaluating emotional well-being and energy/fatigue were assessed through 5 years after treatment with surgery, radiotherapy (with or without androgen deprivation therapy) and active surveillance. Regression models were adjusted for outcome-specific baseline function, demographic and clinicopathological characteristics, and treatment approach.

resultsA total of 2,742 men (median [quartiles] age 64 [59-70]) met inclusion criteria. Baseline depressive symptoms, as measured by the CES-D, were low (median 4, quartiles 1-8) without differences between groups. We found no effect of treatment modality on depressive symptoms (p=0.78), though older age, poorer health, being unmarried and baseline CES-D score were associated with declines in mental health. There was no clinically meaningful association between treatment modality and scores for either emotional well-being (p=0.81) or energy/fatigue (p=0.054).

conclusionsThis prospective, population-based cohort study of men with localized prostate cancer showed no clinically important differences in mental health outcomes including depressive symptoms, emotional well-being, and energy/fatigue according to the treatment received (surgery, radiotherapy, or surveillance). However, we identified a number of characteristics associated with worse mental health outcomes including: older age, poorer health, being unmarried, and baseline CES-D score which may allow for early identification of patients most at risk of these outcomes following treatment.

Indexed as

Androgen AntagonistsProstatic NeoplasmsCohort StudiesFatigueHumansMaleMiddle AgedPatient Reported Outcome MeasuresProspective StudiesQuality of LifeAndrogen Antagonistsmental healthprostatic neoplasmsquality of life

Identifiers

PMID34978488
PMCPMC9933911

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.